Affiliations: [a] Department of Neurology, University of Szeged, Szeged, Hungary | [b] Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary
Correspondence:
[*]
Correspondence to: Professor László Vécsei, Director, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, Department of Neurology, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary. Tel.: +36 (62)545351, 545348; Fax: +36 (62)545597; E-mail: [email protected].
Abstract: Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with dementia as a main feature. Despite decades of thorough research in the field of AD, the pathomechanism is still not fully understood. The development of novel experimental models can help us in the discovery of both genetic and non-genetic components of disease pathogenesis. As currently available therapies in AD can provide merely moderate or only temporary symptomatic relief, there is a great demand for the development of new drugs with higher therapeutic potential. Some of the candidates would be those targeting the kynurenine pathway, the neuroactive metabolites of which are surely involved in both neurodegeneration and neuroprotection, mainly in relation with glutamate excitotoxicity and oxidative stress. Both analogs of the neuroprotective kynurenic acid and small molecule enzyme inhibitors preventing the formation of neurotoxic compounds may have potential therapeutic significance. However, there is a great need for new strategies to improve efficacy, transport across the blood-brain barrier and bioavailability, naturally with simultaneous minimization of the adverse side-effects.
